Biotherapy of neuroendocrine tumours;Biothérapie des tumeurs neuro-endocrinnes

Revue du Praticien

Volumn 52, Issue 3, 2002, Pages 280-284

  Chanson, Philippe ^a   Ducreux, Michel ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

CARCINOID SYNDROME; DRUG BLOOD LEVEL; GASTRINOMA; GLUCAGONOMA; HUMAN; ILEUM; INSULINOMA; NEUROENDOCRINE TUMOR; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HORMONES; HUMANS; INTERFERON-ALPHA; NEUROENDOCRINE TUMORS; QUALITY OF LIFE; SOMATOSTATIN;

EID: 0036469312     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Octreotide
2. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours
3. Rapid reversal of carcinoid crisis with a somatostatin analogue
4. Treatment of the maligrant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue
5. Therapy of the malignant carcinoid syndrome
6. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
7. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide
8. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
9. Somatostatin analogue phase I trials in neuroendocrine neoplasms
10. Metastatic carcinoid tumors and the malignant carcinoid syndrome
11. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial
12. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors
13. The management of patients with advanced carcinoid tumors and islet cell carcinomas
14. Carcinoid crisis during anesthesia: Successful treatment with a somatostatin analogue
15. The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor
16. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide
17. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients
18. Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance
19. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormonerelated symptoms
20. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
21. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide
22. Use of octreotide acetate for control of symptoms in patients with islet cell tumors
23. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma
24. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995)
25. Malignant insulinoma: Effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones
26. Metabolic remission with octreotide in patients with insulinoma
27. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin)
28. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses
29. The use of somatostatin analog in gastroenteropancreatic tumors other than carcinoid
30. Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome
31. Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome
32. Somatostatin analogues in the management of endocrine tumors of the pancreas
33. Treatment of type 11 gastric carcinoid tumors with somatostatin analogues
34. Slow-release lanreotide treatment in endocrine gastrointestinal tumors
35. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases
36. Long term treatment of acromegaly with a long acting analogue of somatostatin
37. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera
38. Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport
39. Vipomas and endocrine cholera: Clinical presentation, diagnosis and advances in management
40. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995
41. Glucagonomas: Clinical presentation, diagnosis and advances in management
42. GRFomas, somatostatinomas: Clinical presentation, diagnosis and advances in management
43. Ectopic adrenocorticotropic hormone syndrome
44. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors
45. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group
46. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours
47. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
48. Anti-tumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
49. Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours
50. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
51. Interferon-alpha 2b, with or without prior hepatic artery embolization: Clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study
52. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: A randomized trial
53. A phase 11 trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors
54. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours
55. Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours
56. Combination therapy with octreotide and alphainterferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors
57. Prospective randomized multicenter trial on the antiproliferative effect of lanreotide, interferon-α and the combination for therapy of metastatic neurodendocrine GEP-tumors